塞库金纽马布和死海气候治疗的影响解决了牛皮皮肤不同潜在影响疾病的记忆力
Thomas Emmanuel1,2, Borislav Ignatov3, Trine Bertelsen1,2
1Department of Dermatology, Aarhus University Hospital, 8200 Aarhus, Denmark.
International journal of molecular sciences
|June 19, 2024
概括
塞库金努马布和死海治疗可以消除牛皮,但会留下明显的分子痕. 基因表达的差异表明,这些痕可能解释了疾病复发和治疗记忆.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 牛皮的治疗方法,如secukinumab和死海气候疗法提供清洁的皮肤,但复发表明潜在的分子变化.
- 这些疗法的独特作用机制暗示着对皮肤生物学产生不同的影响.
研究的目的:
- 为了比较牛皮患者在获得secukinumab和死海气候疗法的完全反应中的分子和遗传差异.
- 调查"分子痕"的概念,有助于疾病复发.
主要方法:
- 皮肤穿孔活检的定量免疫组织化学和转录基因分析.
- 数字空间分析分析皮肤微环境.
- 治疗组之间的基因表达特征的比较.
主要成果:
- 在两种治疗中都观察到病变皮肤的组织学正常化,但转录组仍然改变了.
- 在secukinumab和死海治疗之间,确定了479个差异表达的基因.
- 特定的基因 (SERPINB4,SERPINB13,IL36G,IL36RN,AKR1B10) 在死海治疗时被上调. 泛RAS和IDO1在特定的细胞微环境中表达的差异.
结论:
- 在seukinumab和死海治疗之间,基因表达和微环境概况的差异表明了明显的分子痕.
- 这些分子痕可能是牛皮的疾病复发模式和治疗记忆的基础.
- 了解这些差异对于预测治疗反应持续时间至关重要.
相关概念视频
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
T Cell Types and Functions
999
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
999
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130


